Pharminent

Novo files once-weekly GLP-1 analogue semaglutide

Novo Nordisk has filed its once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide with regulators on both sides of the Atlantic, seeking permission to market the drug for the treatment of adults with type II diabetes. http://www.pharmatimes.com/news/novo_files_once-weekly_glp-1_analogue_semaglutide_1180190

Filed under: Diabetes, GLP-1